The Fully Integrated Solution for Automated Analysis of IHC

Paige has partnered with Mindpeak to bring state-of-the-art AI algorithms for analyzing IHC slides of lung and breast tissue into the Paige Platform. This fully integrated solution supports pathologists in delivering faster, more accurate, and more reproducible cancer diagnoses from within one streamlined diagnostic workflow.

Mindpeak’s robust AI algorithms perform automatic tissue segmentation and the detection, classification, and quantification of tumor cells to provide an automatic clinical score, based on biomarker guideline. With plug and play solutions for PD-L1, HER2, Ki-67, ER and PR quantification now available directly within FullFocus®, pathologists can make clinical decisions with greater confidence and efficiency than ever.

TRY IT FREE FOR 30 DAYS

Why Paige & Mindpeak?

Leverage Paige’s fully open platform to access Mindpeak’s AI applications alongside Paige's robust AI, putting the tools you need for end-to-end diagnosis in one place.

View real-time results from Mindpeak’s IHC biomarker AI algorithms directly within FullFocus®, Paige’s FDA-cleared viewer, creating one seamless workflow to improve lab efficiency.

Reduce the likelihood of error and eliminate tedious manual quantification, simplifying clinical decision-making.

Enhance diagnostic confidence with clinically validated AI support, shown to deliver high performance on images from across different laboratories, stainers, scanners, and antibodies.

Paige_Mindpeak_Partnership_Computer_Image_v2 copy

A New Approach to IHC Biomarker Quantification

Each Mindpeak algorithm performs automatic tissue segmentation to identify invasive tumor areas and detects and classifies tumor cells to calculate a clinical score per biomarker guideline. The score for the complete tumor on the WSI and the single-cell results are displayed directly in FullFocus for final review by the pathologist.

INVASIVE DUCTAL AND LOBULAR CARCINOMA BREAST TISSUE

Mindpeak Breast HER2 | RUO

Upon opening an image in FullFocus, both the HER2 score (acc. ASCO/CAP 2018: 0, 1+, 2+, or 3+) for the complete tumor on the WSI and the single-cell results are displayed to the pathologists for final review

Tumor cells are classified as not-stained (negative), partially stained (partial), completely but weakly stained (complete weak), or completely and strongly stained (complete strong), or unspecific

Mindpeak Ki-67 | RUO

Pathologists can manually select one or many RoIs and the respective proliferation score is directly displayed along with the single-cell results for final review

Hotspot-scoring: An automatic proposal of several pre-scored hotspot alternatives

Global-scoring: The four representative areas according to IKWG-guidelines (negligible, low, medium and strong proliferation) can be automatically proposed, scored and weighted according to overall tumor composition

Mindpeak Breast ER/PR | RUO

ER and PR scoring is facilitated through automated tissue segmentation in order to identify invasive tumor areas as well as detection, classification and quantification of tumor cells in breast cancer tissue

Upon opening an image in FullFocus both the hormone receptor score (ER or PR) for the complete tumor on the WSI and the single-cell results are displayed to the user for final review

INVASIVE NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE

Mindpeak Lung PD-L1 | RUO

PD-L1 scoring is supported through automated tissue segmentation as well as detection, classification, and quantification of tumor cells in non-small cell lung cancer (NSCLC) tissue

Upon opening an image in FullFocus, both the TPS (tumor proportion score) for the complete tumor on the WSI and the single-cell results are displayed to the user for final review

Improve your workflow efficiency and scoring specificity to positively impact patient outcomes with Paige & Mindpeak